These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
273 related articles for article (PubMed ID: 30021814)
1. Ocular preservation with neoadjuvant vismodegib in patients with locally advanced periocular basal cell carcinoma. Sagiv O; Nagarajan P; Ferrarotto R; Kandl TJ; Thakar SD; Glisson BS; Altan M; Esmaeli B Br J Ophthalmol; 2019 Jun; 103(6):775-780. PubMed ID: 30021814 [TBL] [Abstract][Full Text] [Related]
2. Impact of Food and Drug Administration Approval of Vismodegib on Prevalence of Orbital Exenteration as a Necessary Surgical Treatment for Locally Advanced Periocular Basal Cell Carcinoma. Sagiv O; Ding S; Ferrarotto R; Glisson B; Altan M; Johnson F; Elamin Y; Thakar SD; Nagarajan P; Esmaeli B Ophthalmic Plast Reconstr Surg; 2019; 35(4):350-353. PubMed ID: 30365473 [TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant Vismodegib and Mohs Micrographic Surgery for Locally Advanced Periocular Basal Cell Carcinoma. González AR; Etchichury D; Gil ME; Del Aguila R Ophthalmic Plast Reconstr Surg; 2019; 35(1):56-61. PubMed ID: 30444747 [TBL] [Abstract][Full Text] [Related]
5. Outcomes of Vismodegib for Periocular Locally Advanced Basal Cell Carcinoma From an Open-label Trial. Ben Ishai M; Tiosano A; Fenig E; Ben Simon G; Yassur I JAMA Ophthalmol; 2020 Jul; 138(7):749-755. PubMed ID: 32407451 [TBL] [Abstract][Full Text] [Related]
6. Vismodegib as a neoadjuvant treatment to Mohs surgery for aggressive basal cell carcinoma. Alcalay J; Tauber G; Fenig E; Hodak E J Drugs Dermatol; 2015 Mar; 14(3):219-23. PubMed ID: 25738842 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of Vismodegib for the Treatment of Orbital and Advanced Periocular Basal Cell Carcinoma. Eiger-Moscovich M; Reich E; Tauber G; Berliner O; Priel A; Ben Simon G; Elkader AA; Yassur I Am J Ophthalmol; 2019 Nov; 207():62-70. PubMed ID: 31077664 [TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant vismodegib in the management of locally advanced periocular basal cell carcinoma. Curragh DS; Huilgol SC; Selva D Eye (Lond); 2021 Oct; 35(10):2740-2745. PubMed ID: 33235336 [TBL] [Abstract][Full Text] [Related]
10. Staged excision of primary periocular basal cell carcinoma: absence of residual tumour in re-excised specimens: a 10-year series. McGrath LA; Meeney A; Currie ZI; Mudhar HS; Tan JH Br J Ophthalmol; 2019 Jul; 103(7):976-979. PubMed ID: 30181140 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of Vismodegib (Erivedge) for Basal Cell Carcinoma Involving the Orbit and Periocular Area. Demirci H; Worden F; Nelson CC; Elner VM; Kahana A Ophthalmic Plast Reconstr Surg; 2015; 31(6):463-6. PubMed ID: 25675162 [TBL] [Abstract][Full Text] [Related]
12. Role of Vismodegib in the Management of Advanced Periocular Basal Cell Carcinoma. Cox KF; Margo CE Cancer Control; 2016 Apr; 23(2):133-9. PubMed ID: 27218790 [TBL] [Abstract][Full Text] [Related]
14. [Vismodegib Therapy for Periocular Basal Cell Carcinoma]. Keserü M; Green S; Dulz S Klin Monbl Augenheilkd; 2017 Jan; 234(1):64-69. PubMed ID: 28135752 [No Abstract] [Full Text] [Related]
15. Hedgehog Pathway Inhibition for Locally Advanced Periocular Basal Cell Carcinoma and Basal Cell Nevus Syndrome. Ozgur OK; Yin V; Chou E; Ball S; Kies M; William WN; Migden M; Thuro BA; Esmaeli B Am J Ophthalmol; 2015 Aug; 160(2):220-227.e2. PubMed ID: 25935097 [TBL] [Abstract][Full Text] [Related]
16. Oral Hedgehog Pathway Inhibition as a Means for Ocular Salvage in Locally Advanced Intraorbital Basal Cell Carcinoma. Mathis J; Doerr T; Lin E; Ibrahim SF Dermatol Surg; 2019 Jan; 45(1):17-25. PubMed ID: 30586344 [TBL] [Abstract][Full Text] [Related]
17. Vismodegib for periocular basal cell carcinoma: an international multicentre case series. Oliphant H; Laybourne J; Chan K; Haridas A; Edmunds MR; Morris D; Clarke L; Althaus M; Norris P; Cranstoun M; Sullivan TJ; Rajak SN Eye (Lond); 2020 Nov; 34(11):2076-2081. PubMed ID: 31996838 [TBL] [Abstract][Full Text] [Related]
18. Vismodegib for Preservation of Visual Function in Patients with Advanced Periocular Basal Cell Carcinoma: The VISORB Trial. Kahana A; Unsworth SP; Andrews CA; Chan MP; Bresler SC; Bichakjian CK; Durham AB; Demirci H; Elner VM; Nelson CC; Kim DS; Joseph SS; Swiecicki PL; Worden FP Oncologist; 2021 Jul; 26(7):e1240-e1249. PubMed ID: 33988881 [TBL] [Abstract][Full Text] [Related]
19. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial. Dessinioti C; Plaka M; Stratigos AJ Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979 [TBL] [Abstract][Full Text] [Related]
20. Review of Targeted Therapy, Vismodegib, for the Treatment of Periocular Basal Cell Carcinoma. Singalavanija T; Ceylanoglu KS; Juntipwong S; Beser BG; Elner VM; Worden FP; Demirci H Ophthalmic Plast Reconstr Surg; 2024 Jan-Feb 01; 40(1):1-10. PubMed ID: 37552493 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]